Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo

Kee,Ji-Ye; Arita,Yoshihisa; Shinohara,Kanna; Ohashi,Yasukata; Sakurai,Hiroaki; Saiki,Ikuo; Koizumi,Keiichi

doi:10.3892/mco.2012.30

Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo

Authors:
- Ji-Ye Kee
- Yoshihisa Arita
- Kanna Shinohara
- Yasukata Ohashi
- Hiroaki Sakurai
- Ikuo Saiki
- Keiichi Koizumi
View Affiliations

Affiliations: Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan, Department of Cancer Cell Biology, Graduate School Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan, Division of Kampo Diagnostics, Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan
Published online on: September 28, 2012 https://doi.org/10.3892/mco.2012.30
Pages: 35-40

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to their chemoattractant properties stimulating the accumulation of infiltrating immune cells in tumors, chemokines are known to have antitumor effects. Fractalkine, a unique CX3C chemokine, is expressed in activated endothelial cells, while its receptor, CX3CR1, is expressed in cytolytic immune cells, such as natural killer cells, monocytes and some CD8+ T cells. The biological properties of cancer cells are affected by the implantation organ and differences in immune systems, requiring cancer implantation in orthotopic organs in an in vivo experiment. To develop new therapy strategies for lung cancer, an animal model reflecting the clinical features of lung cancer was previously established. This study aimed to determine whether CX3CL1-induced biological functions should be used for immune cell-based gene therapy of lung cancer in the orthotopic implantation model. An orthotopic intrapulmonary implantation of CX3CL1-stable expression in mouse lung cancer (LLC-CX3CL1) was performed to analyze growth. Results showed a significant decrease in tumor growth in the lung compared to the control cells (LLC-mock). Furthermore, the antitumor effects of CX3CL1 were derived from natural killer cell activities in the depletion experiment in vivo. Therefore, CX3CL1 has the potential of a useful therapeutic target in lung cancer.

View Figures

View References

1.	Fidler IJ: Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev. 5:29–49. 1986.
2.	McLemore TL, Egglestone LC, Shoemaker RH, Abbott BJ, Bohlman ME, Liu MC, Fine DL, Mayo JG and Boyd MR: Comparison of intrapulmonary, percutaneous, intrathoracic, and subcutaneous models for the propagation of human pulmonary and non-pulmonary cancer cell lines in athymic nude mice. Cancer Res. 48:2880–2886. 1988.
3.	Yoshie O, Imai T and Nomiyama H: Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol. 62:634–644. 1997.
4.	Yoshie O, Imai T and Nomiyama H: Chemokines in immunity. Adv Immunol. 78:57–110. 2001.
5.	Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ and Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 91:521–530. 1997.
6.	Umehara H, Bloom E, Okazaki T, Domae N and Imai T: Fractalkine and vascular injury. Trends Immunol. 22:602–607. 2001.
7.	Doki Y, Murakami K, Yamaura T, Sugiyama S, Misaki T and Saiki I: Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer. 79:1121–1126. 1999.
8.	Nakamura ES, Koizumi K, Kobayashi M and Saiki I: Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer Sci. 95:25–31. 2004.
9.	Koizumi K, Kozawa Y, Ohashi Y, Nakamura ES, Aozuka Y, Sakurai H, Ichiki K, Doki Y, Misaki T and Saiki I: CCL21 promotes the migration and adhesion of highly lymph node meta-static human non-small cell lung cancer Lu-99 in vitro. Oncol Rep. 17:1511–1516. 2007.
10.	Senda K, Koizumi K, Prangsaengtong O, Minami T, Suzuki S, Takasaki I, Tabuchi Y, Sakurai H, Doki Y, Misaki T and Saiki I: Inducible capillary formation in lymphatic endothelial cells by blocking lipid phosphate phosphatase-3 activity. Lymphat Res Biol. 7:69–74. 2009.
11.	Cho S, Koizumi K, Takeno N, Kato S, Yamada M, Hashimoto I, Sakurai H, Tsukada K and Saiki I: Antitumor effect of combining CC chemokine 22 (CCL22) and an anti-CD25 antibody on myeloma cells implanted subcutaneously into mice. Mol Med Rep. 2:773–777. 2009.
12.	Chada S, Ramesh R and Mhashilkar AM: Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther. 5:463–474. 2003.
13.	D'Elios MM, Del Prete G and Amedei A: New frontiers in cell-based immunotherapy of cancer. Expert Opin Ther Pat. 19:623–641. 2009.
14.	Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zrotnik A and Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature. 385:640–644. 1997.
15.	Imaizumi T, Yoshida H and Satoh K: Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb. 11:15–21. 2004.
16.	Kanazawa N, Nakamura T, Tashiro K, Muramatsu M, Morita K, Yoneda K, Inaba K, Imamura S and Honjo T: Fractalkine and macrophage-derived chemokine: T cell-attracting chemokines expressed in T cell area dendritic cells. Eur J Immunol. 29:1925–1932. 1999.
17.	Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, et al: The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 15:1186–1195. 2003.
18.	Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ and Raines EW: Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 12:37993–38001. 2001.
19.	Yamaura T, Doki Y, Murakami K and Saiki I: Model for mediastinal lymph node metastasis produced by orthotopic intra-pulmonary implantation of lung cancer cells in mice. Hum Cell. 12:197–204. 1999.
20.	Yamaura T, Murakami K, Doki Y, Sugiyama S, Misaki T, Yamada Y and Saiki I: Solitary lung tumors and their spontaneous metastasis in athymic nude mice orthotopically implanted with human non-small cell lung cancer. Neoplasia. 2:315–324. 2000.
21.	Ichiki K, Mitani N, Doki Y, Hara H, Misaki T and Saiki I: Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer. Clin Exp Metastasis. 18:539–545. 2000.
22.	Vicari AP and Caux C: Chemokines in cancer. Cytokine Growth Factor Rev. 13:143–154. 2002.
23.	Koizumi K, Hojo S, Akashi T, Yasumoto K and Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 98:1652–1658. 2007.
24.	Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H and Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 6:3282–3289. 2000.
25.	Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I and Ben-Baruch A: Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59:4681–4687. 1999.
26.	Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H, et al: High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 15:4725–4731. 2007.
27.	Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H and Mori M: The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol. 26:41–47. 2005.
28.	Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R and Tanaka T: Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD⁸⁺ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol. 15:1775–1782. 2008.